Thermo Fisher Scientific, Inc. - TMO STOCK NEWS

Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q1 2022 before the market opens on April 28, 2022, with a conference call scheduled for 8:30 a.m. EST on the same day. The call will outline the company's financial performance and future expectations. Investors can access the call at (844) 200-6205 in the U.S. or (929) 526-1599 internationally, using access code 310385. The press release and additional details will be available on their website.

Thermo Fisher Scientific Inc. (NYSE: TMO) will have its chairman and CEO, Marc N. Casper, present virtually at Cowen’s 42nd Annual Conference on March 7, 2022, at 10:30 a.m. (EST). The conference will be available via webcast on their website. Thermo Fisher, a global leader in serving science, reported annual revenues of approximately $40 billion, supporting advancements in life sciences, diagnostics, and pharmaceutical development.

Thermo Fisher Scientific (NYSE: TMO) has announced a quarterly cash dividend of $0.30 per common share, marking a 15% increase from the previous $0.26. The dividend is payable on April 14, 2022, to shareholders of record as of March 16, 2022. With annual revenues of approximately $40 billion, Thermo Fisher continues to advance its mission of enabling healthier and safer outcomes worldwide.

Moderna and Thermo Fisher Scientific have entered a 15-year strategic collaboration agreement for large-scale manufacturing of mRNA vaccines, including Spikevax®, in the U.S. This partnership aims to enhance manufacturing capacity and efficiency for Moderna's investigational mRNA medicines. Thermo Fisher will provide dedicated aseptic fill-finish services, packaging, and inspection to support Moderna's ongoing development efforts. The collaboration builds on their existing relationship that has successfully supported Moderna's COVID-19 vaccine production.

Thermo Fisher Scientific has expanded its Applied Biosystems portfolio with the new SeqStudio Flex Series Genetic Analyzer, aimed at enhancing clinical research and scientific discovery in areas like gene editing and infectious diseases. This mid-throughput genetic analyzer boasts increased plate capacity, simplified workflows, and advanced Wi-Fi connectivity for remote monitoring. Celebrating 40 years of the Applied Biosystems brand, Thermo Fisher emphasizes ongoing investments in capillary electrophoresis technology, which is central to its sequencing portfolio.

Thermo Fisher Scientific has announced a multiyear partnership with Medidata Acorn AI to develop PPD TrueCast, an advanced platform for enhancing clinical trial performance.

This application integrates machine learning and predictive analytics, leveraging data from over 40,000 trial sites and 50,000 investigators. It aims to optimize site selection, trial enrollment, and study cycle times, potentially reducing Phase III study enrollment by 1.5 months and improving milestone forecasting accuracy by 30%.

Thermo Fisher Scientific has launched the Renvo Rapid PCR Test, a rapid environmental testing solution for detecting SARS-CoV-2 pathogens in air samples. This test provides results in just 30 minutes, significantly faster than previous 4-24 hour methods. Designed for communal spaces like schools and healthcare facilities, it enhances indoor air monitoring for COVID-19. Utilizing proprietary Oscar PCR technology, this test strengthens risk mitigation efforts in public areas.

Thermo Fisher Scientific (TMO) reported strong financial results for Q4 and full-year 2021. Q4 revenue hit $10.70 billion, with diluted EPS at $4.17 and adjusted EPS at $6.54. For the full year, revenue surged 22% to $39.21 billion, with GAAP EPS increasing 22% to $19.46. The company achieved $9.23 billion in COVID-19 response revenue and invested $2.5 billion to enhance capacity. In acquisitions, TMO deployed $24 billion, including PPD, Inc., and PeproTech, while committing to net-zero carbon emissions by 2050.

Thermo Fisher Scientific (NYSE:TMO) has completed its acquisition of PeproTech for approximately $1.85 billion on December 30, 2021. PeproTech specializes in recombinant proteins such as cytokines and growth factors, which are integral to cell and gene therapy development. This acquisition enhances Thermo Fisher's biosciences portfolio, allowing for improved offerings to pharma and biotech clients. CEO Marc Casper highlighted that the integration will leverage existing capabilities and foster growth in the expanding cell therapy market.